7Baggers
 Australian patent office accepts Dermata’s acne treatment patent  Investing.com Australia Thu, 02 Oct 2025 12:25:11 GMT
 Primary Axillary Hyperhidrosis Pipeline 2025: Key Clinical  openPR.com Thu, 02 Oct 2025 00:02:03 GMT
 Published on: 2025-09-18 21:39:59  خودرو بانک Thu, 18 Sep 2025 18:13:02 GMT
 dermata therapeutics presents promising phase 3 trial results  TipRanks Wed, 17 Sep 2025 07:00:00 GMT
  Financial Post Wed, 17 Sep 2025 00:46:13 GMT
  Financial Post Tue, 16 Sep 2025 18:46:13 GMT
 published on: 2025-09-11 19:20:42  Newser Fri, 12 Sep 2025 00:20:42 GMT
 published on: 2025-09-10 02:32:09  Newser Wed, 10 Sep 2025 07:32:09 GMT
 Dermata Therapeutics climbs on acne product shift  TradingView Wed, 10 Sep 2025 07:00:00 GMT
 Dermata Shifts Focus to Over-the-Counter Dermatology  TipRanks Wed, 10 Sep 2025 07:00:00 GMT
 dermata therapeutics withdraws ind application for xyngari  TipRanks Wed, 10 Sep 2025 07:00:00 GMT

Dermata Therapeutics, Inc.
(NASDAQ:DRMA) 

DRMA stock logo

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clin...

Founded: 2014
IPO Price: $7 (Aug 13, 2021)
Full Time Employees: 8
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends